Highest-materiality recent filing
Outset Medical secures ~$40M HCA commitment for Tablo hemodialysis system refresh through 2028
HCA commits to purchase new Tablo hemodialysis consoles from 2026 through 2028 under Refresh Amendment; aggregate contract value ~$40M net of rebates.
Outset Medical annual meeting results: directors elected, say-on-pay approved, KPMG ratified
Brent D. Lang and Karen Prange elected as Class III directors to serve until 2029 annual meeting.
EVP R&D, Operations and Service Marc Nash to depart Outset Medical June 5
Marc Nash resigned as EVP R&D, Operations and Service effective June 5, 2026.
Outset Medical Q1 revenue down 6% to $27.9M; gross margin expands to 43.4%
Revenue $27.9M (-6% YoY); recurring revenue $22.5M roughly flat.
Outset Medical reports FY2025 revenue $119.5M (+5% YoY); provides 2026 guidance $125-130M
Q4 revenue $28.9M; full year 2025 revenue $119.5M (+5% YoY); recurring revenue $88.7M (+6%).
FDA 510(k) clearance granted for next-gen Tablo platform on January 27, 2026.
Outset Medical prelim Q4 rev $28.9M; FY2025 rev $119.5M (+5% YoY); cash $173M; appoints Prange
Q4 2025 revenue ~$28.9M; full-year 2025 revenue $119.5M, up 5% from $113.7M in 2024.
Outset Medical Q3 revenue $29.4M (+3%); cuts FY 2025 revenue guidance to $115-120M
Net loss $17.8M vs $27.9M a year ago; non-GAAP net loss $12M vs $20.2M.
Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M
Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).
Outset Medical appoints Renee Gaeta as CFO; reaffirms $115M-$125M revenue guidance
Renee Gaeta appointed CFO effective June 3, 2025; succeeds Nabeel Ahmed who is leaving.
Outset Medical appoints Kevin O'Boyle to board, Dale Jones resigns
Dale E. Jones stepped down from the Board effective May 14, 2025; no disagreement with company.
Outset Medical Q1 revenue up 6%, gross margin expands to 37.2%, net loss narrows
Net revenue $29.8M (+6% YoY); recurring Tablo consumables & services $22.7M (+20% YoY).
Outset Medical effects 1-for-15 reverse stock split effective March 20, 2025
Reverse stock split at ratio of 1-for-15, effective 12:01 a.m. ET on March 20, 2025.
Outset Medical announces 1-for-15 reverse stock split effective March 20, 2025
Reverse split ratio set at 1-for-15; outstanding shares to drop from ~265M to ~17M.
Outset Medical Series A conversion adds 210.7M shares; total common now 265.5M
On March 7, 2025, issued 19,432 Series A Non-Voting Convertible Preferred shares to directors, officers, and employees after stockholder approval.
Outset Medical stockholders approve reverse stock split and preferred stock issuance
Approved reverse stock split at ratio of 1:10 to 1:15, board discretion within one year.
Outset Medical receives second Nasdaq delisting notice; FY2024 revenue $113.7M, down 13%
Nasdaq notified Outset on Feb 24, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure period until Aug 25, 2025.
Q4 revenue $29.5M (+3% QoQ, -3% YoY); full-year $113.7M, beating prior guidance.
Outset Medical amends bylaws to adopt majority-of-votes-cast standard for stockholder matters
Board adopted Amendment No. 1 to Bylaws on January 23, 2025, effective immediately.
Outset Medical secures $100M term loan, issues warrants and Series A Preferred in refinancing
Borrowed $100M initial term loan from Perceptive Credit Holdings; used proceeds to repay existing SLR credit facilities.
Private placement of 843,908 Series A convertible preferred shares at $200/share for ~$168.8M gross proceeds; insiders to invest additional $3.9M subject to shareholder approval.
Outset Medical Q3 revenue $28.7M, net loss $0.55/share; raises FY2024 revenue guidance to ~$112M
Revenue $28.7M down 6% YoY but up 5% QoQ; product revenue $20.3M down 14% YoY.
Outset Medical receives Nasdaq delisting notice for bid price below $1.00 for 30 days
Notice dated Sept 23, 2024: closing bid price below $1.00 for 30 consecutive days violates Nasdaq Listing Rule 5450(a)(1).
Director Jim Hinrichs resigns from Outset Medical board; Hackett named Audit Chair
Jim Hinrichs resigned as director and Audit Committee Chair due to affiliation with Vantive, Baxter's kidney care spin-off.
Outset Medical Q2 revenue $27.4M (-24% YoY); FY2024 guidance cut to ~$110M from $145-153M
Product revenue fell to $19.2M; service revenue rose 21.5% to $8.2M.
Outset Medical shareholders re-elect three directors; say-on-pay approved by narrow margin
Class I directors re-elected: Drexler (25.8M for, 7.6M withheld), Jones (32.6M for, 0.8M withheld), Trigg (32.1M for, 1.3M withheld). Broker non-votes: 5.1M.
Outset Medical Q1 revenue $28.2M, net loss $(0.78)/share; CTO departs, $3.0M restructuring
Revenue $28.2M, down 16% YoY; service revenue up 36% to $7.7M, recurring revenue up 24%.
Outset Medical receives FDA 510(k) clearance for TabloCart with Prefiltration; resumes distribution
FDA granted 510(k) clearance for TabloCart with Prefiltration, an accessory for the Tablo Hemodialysis System.
Outset Medical appoints Brent Lang to board; Director Szyman resigns for Edwards spinoff CEO role
Brent D. Lang appointed to the board effective March 12, 2024, filling vacancy left by Catherine Szyman.
Outset Medical Q4 revenue $30.5M, FY revenue $130.4M; CCO Steve Williamson departs March 1
FY 2023 revenue $130.4M (+13% YoY); Q4 revenue $30.5M (-4.7% YoY) due to product revenue decline.
Outset Medical reports Q4 rev $30.5M, FY2023 $130M (+13%), guides 2024 rev $145-153M
Q4 revenue $30.5M; FY2023 revenue $130M, up 13% YoY.
Outset Medical borrows $66.5M under SLR term loan facility; outstanding now $200M
Borrowed $66.5M on Jan 2, 2024 under existing SLR Term Loan Facility.
Outset Medical borrows $33.5M under amended SLR term loan; total debt ~$133.5M
On Dec 11, 2023, Outset amended its SLR term loan, restructuring the $100M Term B into two tranches: B-1 ($33.5M) and B-2 ($66.5M).
Outset Medical Q3 revenue $30.4M (+9% YoY); net loss $46.2M; reiterates FY23 guidance ~$130M
Revenue $30.4M, +9% YoY; product rev $23.5M (+8.2%), service rev $6.8M (+13.4%).
Outset Medical prelim Q3 rev $30.4M (+9% YoY); FY23 guidance cut to ~$130M on FDA letter headwind
Preliminary Q3 revenue $30.4M (+9% YoY), gross margin 23.6% (25.6% non-GAAP).
Outset Medical Q2 revenue $36M (+44% YoY); pauses TabloCart shipment pending 510(k) clearance
Q2 net revenue $36.0M, up 44% YoY; product revenue $29.3M (+49.5%).
FDA Warning Letter to Outset Medical over Tablo System promotion and TabloCart clearance
FDA Warning Letter dated July 5, 2023 received July 6, 2023, citing two observations: promotional material for CRRT outside Tablo indications, and TabloCart needing 510(k) clearance.
Outset Medical shareholders elect three Class III directors at 2023 annual meeting
Jim Hinrichs elected with 31,328,771 votes for, 9,103,234 withheld.
Outset Medical Q1 revenue $33.5M (+9.5% YoY); raises FY2023 revenue and margin guidance
Revenue $33.5M, up 9.5% YoY; product revenue $27.8M (+8.2%), service revenue $5.7M (+16.4%).
Outset Medical Q4 revenue $32M (+14% YoY); COO Vazquez retiring Apr 3
Q4 revenue $32.0M (+14% YoY); full-year revenue $115.4M (+12.4% YoY).
Outset Medical reports Q4 2022 expected revenue ~$31.5M; guides FY2023 revenue $140-150M
Q4 2022 expected revenue ~$31.5M (+13% QoQ); FY2022 expected revenue ~$115M (+12% YoY).
Outset Medical Q3 revenue $27.8M (+5.5% YoY); raises 2022 guidance to $111-113M
Revenue $27.8M, +5.5% YoY and +10.8% QoQ; gross margin 15.6% vs 11.2% YoY.
Outset Medical secures up to $300M in debt financing from SLR Capital Partners
Term loan facility up to $250M; $100M drawn at closing with $200M committed initially.
Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M
Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).
Outset Medical halts home Tablo shipments pending FDA 510(k) review; guides Q2 rev at least $25M
Shipment hold on new Tablo Hemodialysis Systems for home use pending FDA 510(k) clearance of post-March 2020 changes.
Outset Medical Annual Meeting: two Class II directors elected, say-on-pay approved, auditor ratified
D. Keith Grossman and Patrick T. Hackett elected Class II directors until 2025 annual meeting.
Outset Medical Q1 revenue $30.6M (+33% YoY); narrows FY2022 guidance to $144M-$150M
Revenue $30.6M (+33.3% YoY); product revenue $25.7M (+40.9%).
Outset Medical appoints Dale E. Jones to Board and Compensation Committee
Board expanded from 7 to 8 directors; Jones appointed as class I director effective April 21, 2022.
Outset Medical Q4 revenue $28.2M, FY21 $102.6M (+105%); guides FY22 $142-150M; CEO adds Chair
Q4 revenue $28.2M (+63% YoY); FY21 revenue $102.6M (+105.5% YoY). GAAP EPS ($0.87); non-GAAP EPS ($0.77).
Outset Medical Q3 revenue $26.3M, up 91% YoY; raises 2021 guidance to $99-101M
Revenue $26.3M (+91.3% YoY); product revenue $21.8M (+101.9% YoY).
On May 26, 2026, Marc Nash informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company and his role as Executive Vice President, R&D, Operations and Service, effective June 5, 2026, to pursue other professional opportunities.
On May 30, 2025, the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”) appointed Renee Gaeta as the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective June 3, 2025.
On May 12, 2025, the Board appointed Kevin O’Boyle as a new member of the Board and as a member and Chair of the Audit Committee of the Board, with such appointment effective May 14, 2025.
On May 10, 2025, Dale E. Jones, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), stepped down from the Board, effective May 14, 2025.
On August 15, 2024, Jim Hinrichs, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), notified the Company of his decision to resign from the Board and his role as Audit Committee Chair, effective immediately.
Jean-Olivier Racine will depart from his role as the Company's Chief Technology Officer, effective May 17, 2024, in connection with the workforce reduction plan described in Item 8.01 below.
On March 8, 2024, Catherine Szyman, a member of the Board of Directors (the “Board”) of Outset Medical, Inc. (the “Company”), resigned from the Board in preparation for her pending role as Chief Executive Officer of Edwards Lifesciences’ Critical Care spinoff, with such resignation effective March 12, 2024.
On March 10, 2024, the Board appointed Brent D. Lang as a new member of the Board and as a member of the Audit Committee of the Board, with such appointment effective March 12, 2024.
On February 16, 2024, Steve Williamson informed the Company of his decision to depart from the Company and his role as Chief Commercial Officer, effective March 1, 2024, to become the CEO of another publicly traded medical device company.
On February 13, 2023, Martin Vazquez informed the Company of his decision to retire from his role as Chief Operating Officer of the Company effective April 3, 2023 to pursue personal opportunities.
On April 21, 2022, the Board of Directors (the “ Board ”) of Outset Medical, Inc. (the “ Company ”) determined to increase the size of the Board from seven (7) directors to eight (8) directors and appointed Dale E. Jones as a new member of the Board and as a member of the Compensation Committee of the Board, with such appointment to be effective immediately.
On August 5, 2021, the Company announced the Board of Director’s approval of Mr. Ahmed’s transition to the permanent role of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective July 30, 2021
Max materiality 0.90 · Median 0.70 · Most common event earnings